Key result
Concomitant administration of PRV and OPV was noninferior to staggered administration for achieving poliovirus seroprotection (>98% in the concomitant group) and antirotavirus IgA seroresponse.
Why the study?
Does concomitant administration of PRV and OPV maintain noninferior immunogenicity compared to staggered administration in healthy infants?
Population
735 healthy 6- to 12-week-old Latin American infants who did not receive OPV at birth
Comparison
Oral pentavalent rotavirus vaccine and oral… vs PRV administered 2-4 weeks before OPV
Design
RCT, randomized, open-label
Follow-up
42 days after the last dose
Authors
Loading...
Supports coadministration of PRV and OPV in infant schedules; extends evidence for integrated vaccination programs.
RCT (n=735)
Open-label
randomized
Yes
Does concomitant administration of PRV and OPV maintain noninferior immunogenicity compared to staggered administration in healthy infants?
Coadministration of PRV and OPV does not interfere with poliovirus immune responses and maintains high rotavirus seroresponse rates, supporting their concomitant use in vaccination schedules.
Ciarlet et al. (2008) conducted an RCT in Healthy infants (n=735). Concomitant oral pentavalent rotavirus vaccine (PRV) and oral poliovirus vaccine (OPV) vs. PRV 2-4 weeks before OPV (staggered use) was evaluated on Serum-neutralizing antibody titer ≥ 1:8 against poliovirus types 1, 2, and 3. Concomitant administration of PRV and OPV was noninferior to staggered administration for achieving poliovirus seroprotection (>98% in the concomitant group) and antirotavirus IgA seroresponse.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: